Mostafa TM, Alm El-Din MA, Rashdan AR (2022) Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer A randomized controlled clinical study. Saudi Med J 43(1):37–44. https://doi.org/10.15537/SMJ.2022.43.1.20210574

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Goding Sauer A et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70(3):145–164. https://doi.org/10.3322/caac.21601

Article  PubMed  Google Scholar 

Lou Y, Wang Q, Zheng J et al (2016) Possible pathways of Capecitabine-Induced Hand-Foot syndrome. Chem Res Toxicol 29(10):1591–1601. https://doi.org/10.1021/acs.chemrestox.6b00215

Article  CAS  PubMed  Google Scholar 

Santhosh A, Kumar A, Pramanik R et al (2022) Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Trials 23(1). https://doi.org/10.1186/s13063-022-06353-2

Hiromoto S, Kawashiri T, Yamanaka N et al (2021) Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. Sci Rep 11(1):8964. https://doi.org/10.1038/s41598-021-88460-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JC, Wang JC, Pan YX et al (2020) Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial. Am J Cancer Res 10(5):1467–1476. www.ajcr.us/

CAS  PubMed  PubMed Central  Google Scholar 

Alsaloumi L, Alsaloumi L, Shawagfeh S, Başgut B Hand and foot syndrome associated with capecitabine. Annals of clinical oncology. Published Online August 25, 2020:1–6. https://doi.org/10.31487/j.aco.2020.02.03

Zhang L, Li M, Wang W et al (2022) Celecoxib alleviates denervation-induced muscle atrophy by suppressing inflammation and oxidative stress and improving microcirculation. Biochem Pharmacol 203. https://doi.org/10.1016/j.bcp.2022.115186

Kao YS, Lo CH, Tu YK et al (2022) Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. Dermatol Ther 35(10). https://doi.org/10.1111/dth.15774

Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23(5):1348–1353. https://doi.org/10.1093/annonc/mdr400

Article  CAS  PubMed  Google Scholar 

Schulz, KF ADMD. for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Sibaud V, Dalenc F, Chevreau C et al (2011) HFS-14, a specific quality of life scale developed for patients suffering from Hand–Foot syndrome. Oncologist 16(10):1469–1478. https://doi.org/10.1634/theoncologist.2011-0033

Article  PubMed  PubMed Central  Google Scholar 

Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy - Classification and management. JDDG - J German Soc Dermatology 8(9):652–661. https://doi.org/10.1111/j.1610-0387.2010.07449.x

Article  Google Scholar 

Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71(4):787–794. https://doi.org/10.1016/j.jaad.2014.03.019

Article  PubMed  Google Scholar 

Webster-Gandy JD, How C, Harrold K (2007) Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11(3):238–246. https://doi.org/10.1016/j.ejon.2006.10.004

Article  PubMed  Google Scholar 

Milano G, Etienne-Grimaldi MC, Mari M et al (2008) Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 66(1):88–95. https://doi.org/10.1111/j.1365-2125.2008.03159.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12(3):131–141. https://doi.org/10.1177/1078155206069242

Article  CAS  PubMed  Google Scholar 

Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan D, Sen, Chen G (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: A phase II randomized prospective study. J Cancer Res Clin Oncol 137(6):953–957. https://doi.org/10.1007/s00432-010-0958-9

Article  CAS  PubMed  Google Scholar 

Lin EMJAG (2002) Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 14(12):31–37

Google Scholar 

Lee JS, Kim HS, Hahm KB, Surh YJ (2020) Effects of genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated carcinogenesis in mice. J Cancer Prev 25(1):27–37. https://doi.org/10.15430/jcp.2020.25.1.27

Article  PubMed  PubMed Central  Google Scholar 

Alqahtani AMCKPFACBDPVK (2021) Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer. Eur Rev Med Pharmacol Sci 25(4):1916–1927

CAS  PubMed  Google Scholar 

Vio CP, Quiroz-Munoz M, Cuevas CA, Cespedes C, Ferreri NR (2012) Prostaglandin E 2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney. Am J Physiol Ren Physiol 303:449–457. https://doi.org/10.1152/ajprenal.00634.2011.-Cyclooxy

Article  Google Scholar 

Konturek PC, Rembiasz K, Burnat G et al (2006) Effects of cyclooxygenase-2 Inhibition on serum and tumor Gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci 51(4):779–787. https://doi.org/10.1007/s10620-006-3206-z

Article  CAS  PubMed  Google Scholar 

Aggarwal BB, Gupta SC, Sung B (2013) Theme section: emerging therapeutic aspects in oncology curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169(8):1672–1692. https://doi.org/10.1111/bph.2013.169.issue-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Y, Liu J, Wang LZ, Zhang WY, Zhu XZ (2005) Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons. Acta Pharmacol Sin 26(8):952–958. https://doi.org/10.1111/j.1745-7254.2005.00136.x

Article  CAS  PubMed  Google Scholar 

Lee BNJSDMEJKDSJCRPAFHYRLJ (2016) Influence of chemotherapy on the antioxidant status of human skin. Anticancer Res 36(8):4089–4093

CAS  PubMed  Google Scholar 

Tavakoli Pirzaman A, Mansoori R, Hosseini SM et al (2024) The effect of melatonin on capecitabine-induced hepatic and renal toxicity in rats. Hum Exp Toxicol 43. https://doi.org/10.1177/09603271231223506

Houshmand G, Naghizadeh B, Ghorbanzadeh B, Ghafouri Z, Goudarzi M, Mansouri MT (2020) Celecoxib inhibits acute edema and inflammatory biomarkers through peroxisome proliferator-activated receptor-γ in rats. Iran J Basic Med Sci 23(12):1544–1550. https://doi.org/10.22038/ijbms.2020.43995.10315

Article  PubMed  PubMed Central  Google Scholar 

Dixit A, Pandey P, Dhasmana D (2020) Vivo effects of Nonselective, partially selective, and selective Non steroidal anti-inflammatory drugs on lipid peroxidation and antioxidant enzymes in patients with rheumatoid arthritis: A clinical study. Int J Appl Basic Med Res 10(3):167. https://doi.org/10.4103/ijabmr.ijabmr_344_19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ekor M, Odewabi AO, Kale OE, Adesanoye OA, Bamidele TO (2013) Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats. Drug Chem Toxicol 36(1):1–8. https://doi.org/10.3109/01480545.2011.642380

Article  CAS  PubMed  Google Scholar 

Ajith TA, Subin JP, Jacob J, Sanjay PS, Babitha NV (2005) Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib. Clin Exp Pharmacol Physiol 32(10):888–893. https://doi.org/10.1111/j.1440-1681.2010.04280.x

Article  CAS  PubMed  Google Scholar 

Mouithys-Mickalad AML, Zheng SX, Deby-Dupont A’c (2000) In vitro study of the antioxidant properties of Non steroidal Anti-Inflammatory drugs by chemiluminescence and Electron spin resonance (ESR). Free Rad Res 33(5):607–621

Article  CAS  Google Scholar 

Chen EY, Blanke CD, Haller DG et al (2018) A phase II study of celecoxib with irinotecan, 5-Fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal Cancer. Am J Clin Oncology: Cancer Clin Trials 41(12):1193–1198. https://doi.org/10.1097/COC.0000000000000465

Article  CAS  Google Scholar 

Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: A review. Ther Adv Med Oncol 8(1):57–84. https://doi.org/10.1177/1758834015614530